Wadenswil, Switzerland
GlycoEra AG, headquartered in Switzerland, is at the forefront of the biotechnology sector with its slogan, "Advancing Glycan Mediated Therapy." Founded in 2020, the company is pioneering a novel approach to treating autoimmune diseases by developing biologics targeted at specific circulating proteins, known as autoantibodies.
Their groundbreaking platform, BiND™ (Biologic Natural Degrader), provides the ability to target and degrade proteins quickly and deeply. This targeted strategy offers significant advantages over traditional therapies, potentially improving patient quality of life, minimizing complications, and reducing healthcare costs.
GlycoEra's recent financial momentum is underscored by a $130.00M Series B investment received on 01 May 2025, drawing significant interest from prominent investors including Novo Holdings, Sofinnova Partners, and Bristol-Meyers Squibb, among others. This strong backing from major industry players indicates a promising path for GlycoEra's continued innovation and growth.
